Displaying all 3 publications

Abstract:
Sort:
  1. Fulltext A prospective comparison of UK and Malaysian patients with irritable bowel syndrome in secondary care
    Chuah KH, Black CJ, Tee V, Lim SZ, Hian WX, Sahran NF, et al.
    Aliment Pharmacol Ther, 2023 Jul;58(2):168-174.
    PMID: 37259882 DOI: 10.1111/apt.17567
    BACKGROUND: The prevalence of irritable bowel syndrome (IBS) is now known to be similar in various geographical regions, but there has been no study directly comparing characteristics of patients with IBS between populations.

    AIMS: To evaluate clinical and psychological differences between adults with IBS seen in secondary care in the United Kingdom (UK) and Malaysia.

    METHODS: Age- and sex-matched patients with IBS from a single centre in the UK (Leeds) and two centres in Malaysia (Kuala Lumpur and Kota Bharu), who fulfilled Rome III criteria, were recruited prospectively. Demographic characteristics and gastrointestinal and psychological symptoms were compared between both groups.

    RESULTS: A total of 266 (133 UK and 133 Malaysian) age- and sex-matched patients with Rome III IBS were recruited (mean age: 45.1 years Malaysia, vs. 46.5 years UK; 57.9% female). UK patients were more likely to consume alcohol than Malaysian patients (54.1% vs. 10.5%, p 

  2. Editorial: Recognising the regional variations in profile of irritable bowel syndrome-better late than never! Authors' reply
    Chuah KH, Black CJ, Tee V, Lim SZ, Hian WX, Sahran NF, et al.
    Aliment Pharmacol Ther, 2023 Aug;58(4):476-477.
    PMID: 37499105 DOI: 10.1111/apt.17634
  3. Efficacy and safety of nab-paclitaxel in metastatic gastric cancer: a meta-analysis
    Ahmad S, Lambuk L, Ahmed N, Mussa A, Tee V, Mohd Idris RA, et al.
    Nanomedicine (Lond), 2023 Oct;18(24):1733-1744.
    PMID: 37982749 DOI: 10.2217/nnm-2022-0300
    Background: Nab-paclitaxel is formulated to address several limitations of paclitaxel. Methods: A systematic review was done of several databases and a meta-analysis with a random-effects model was conducted to assess the efficacy and safety of nab-paclitaxel in metastatic gastric cancer (MGC). Results: Included studies revealed that nab-paclitaxel provides a 30.4% overall response rate and 65.7% disease control rate in MGC patients. The overall survival was 9.65 months and progression-free survival was 4.48 months, associated with the treatment line and regimen. The highest incidence of grade 3 and higher treatment-related adverse events was for neutropenia (29.9%). Conclusion: Nab-paclitaxel provides better disease response and longer survival with manageable side effects in MGC compared with paclitaxel.
Related Terms
    Try searching for something
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links